Prescription medication · Immunosuppressant (Ophthalmic)
cyclosporine ophthalmic
Also sold as Restasis, Cequa. VEVYE treats dry eye disease.
Data updated 2026-05-15
- $9.38
- Brand price (NADAC)
cyclosporine ophthalmic (Restasis) is a prescription Immunosuppressant (Ophthalmic). VEVYE treats dry eye disease.
VEVYE eye drops contain cyclosporine. They help treat the signs and symptoms of dry eye disease.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Brand Price
$9.38/unit
Generic Available
No
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
VEVYE treats dry eye disease.
Common side effects
Irritation where the drop is applied
Key warnings
To avoid injury or contamination, do not touch your eye or other surfaces with the bottle tip.
The sections below are summarized in plain English from cyclosporine ophthalmic's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
VEVYE contains cyclosporine, which is a type of medicine that lowers your body's immune response in the eye. It reduces inflammation. This helps your eyes make more tears.
Serious Warnings
To avoid injury or contamination, do not touch your eye or other surfaces with the bottle tip. Do not use VEVYE while wearing contact lenses. If you wear contacts, take them out before using the drops. You can put them back in 15 minutes after using the drops.
Common Questions
What is the strength of VEVYE?
How often should I use VEVYE?
Can I use VEVYE with my contact lenses?
What should I do if the bottle tip touches my eye?
How should I store VEVYE?
What if I accidentally swallow VEVYE?
Can I use VEVYE if I am pregnant?
Can I use VEVYE if I am breastfeeding?
What should I do if I experience blurry vision after using VEVYE?
How long can I use VEVYE after opening the bottle?
What are the common side effects of cyclosporine ophthalmic?
What drug class is cyclosporine ophthalmic?
What pregnancy or breastfeeding source fields are listed for cyclosporine ophthalmic?
Related Medications in Immunosuppressant (Ophthalmic)
Other drugs grouped near cyclosporine ophthalmic - same-class peers and common alternatives.
aflibercept
Eylea
AHZANTIVE is a medicine used to treat certain eye problems.
Compare with cyclosporine ophthalmic →
artificial tears
Refresh, Systane
Artificial tears are eye drops that lubricate your eyes.
Compare with cyclosporine ophthalmic →
bevacizumab (ophthalmic)
Avastin
Avastin is a medicine that blocks a protein called vascular endothelial growth factor (VEGF).
Compare with cyclosporine ophthalmic →
bimatoprost
Lumigan
Bimatoprost eye drops help lower pressure in the eye.
Compare with cyclosporine ophthalmic →
brimonidine ophthalmic
Alphagan P
Alphagan P eye drops help lower pressure in the eye.
Compare with cyclosporine ophthalmic →
Compare cyclosporine ophthalmic vs aflibercept side-by-side →
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on cyclosporine ophthalmic
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for cyclosporine ophthalmic
The FDA label for cyclosporine ophthalmic (sold under brand names such as Restasis, Cequa) classifies it as a prescription-only medication in the Immunosuppressant (Ophthalmic) class. VEVYE treats dry eye disease. Official labeling lists 1 commonly reported side effect, including Irritation where the drop is applied.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. Voluntary reports accumulate over the lifetime of a drug and reflect wide-ranging clinical use. Interaction data is drawn directly from FDA-approved prescribing information. NADAC pricing from CMS.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: November 14, 2025
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages